Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$8.86 +2.0%	$7.84	$4.58 ▼ $9.48	$435.08M	1.88	1.08 million shs	518,531 shs
EQ Equillium	$1.74 -4.4%	$0.71	$0.27 ▼ $2.26	$108.30M	1.15	23.50 million shs	1.61 million shs
ITOS iTeos Therapeutics	$10.15	$10.14	$4.80 ▼ $17.63	$448.73M	1.49	1.64 million shs	N/A
REPL Replimune Group	$5.40 +0.4%	$7.38	$2.68 ▼ $17.00	$419.94M	0.67	4.93 million shs	2.25 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	+1.96%	-1.23%	+17.51%	+46.20%	+1.49%
EQ Equillium	-4.40%	-8.42%	+352.42%	+383.47%	+70.59%
ITOS iTeos Therapeutics	+0.83%	+0.43%	+1.13%	+2.55%	-40.33%
REPL Replimune Group	+0.37%	-4.76%	-28.48%	-39.53%	-47.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYRX CryoPort	3.9203 of 5 stars	4.5	1.0	0.0	3.5	2.5	1.9
EQ Equillium	1.0723 of 5 stars	1.0	5.0	0.0	3.3	1.7	0.0
ITOS iTeos Therapeutics	2.7027 of 5 stars	3.1	3.0	0.0	2.2	3.3	0.6
REPL Replimune Group	3.8519 of 5 stars	3.1	2.0	4.5	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	3.00	Buy	$12.00	35.44% Upside
EQ Equillium	2.00	Hold	$1.00	-42.53% Downside
ITOS iTeos Therapeutics	2.14	Hold	$15.50	52.71% Upside
REPL Replimune Group	2.10	Hold	$6.50	20.37% Upside

Current Analyst Ratings Breakdown

Latest EQ, ITOS, CYRX, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
8/6/2025	CYRX CryoPort	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$15.00
8/6/2025	CYRX CryoPort	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$16.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$228.38M	1.94	N/A	N/A	$9.53 per share	0.93
EQ Equillium	$41.10M	2.52	N/A	N/A	$0.08 per share	21.75
ITOS iTeos Therapeutics	$35M	12.82	N/A	N/A	$11.17 per share	0.91
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	-$114.76M	$1.33	6.66	N/A	N/A	37.21%	-9.79%	-5.42%	11/6/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-139.56%	-90.56%	11/12/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$4.67	N/A	N/A	N/A	N/A	-33.26%	-28.16%	11/11/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	11/11/2025 (Estimated)

Latest EQ, ITOS, CYRX, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
8/6/2025	Q2 2025	ITOS iTeos Therapeutics	-$1.12	-$1.51	-$0.39	-$1.81	N/A	N/A
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	-$0.29	-$0.09	$2.05	$41.74 million	$45.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	0.39	16.24	15.47
EQ Equillium	N/A	1.65	1.65
ITOS iTeos Therapeutics	N/A	7.53	7.53
REPL Replimune Group	0.21	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
EQ Equillium	27.05%
ITOS iTeos Therapeutics	97.16%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	10.00%
EQ Equillium	31.60%
ITOS iTeos Therapeutics	14.20%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	1,186	50.07 million	45.06 million	Optionable
EQ Equillium	40	59.50 million	40.70 million	Not Optionable
ITOS iTeos Therapeutics	90	44.21 million	37.93 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

EQ, ITOS, CYRX, and REPL Headlines

Recent News About These Companies

Replimune Group, Inc. $REPL Shares Sold by Wellington Management Group LLP

August 30 at 4:13 AM | marketbeat.com

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

August 29 at 11:10 AM | prnewswire.com

REPL Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed

August 29 at 7:56 AM | globenewswire.com

Vanguard Group Inc. Increases Stock Position in Replimune Group, Inc. $REPL

August 29 at 3:14 AM | marketbeat.com

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors - Contact Levi & Korsinsky

August 29 at 2:31 AM | theglobeandmail.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

August 28 at 10:31 PM | globenewswire.com

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline

August 28 at 9:30 PM | theglobeandmail.com

REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit

August 28 at 8:20 PM | prnewswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

August 28 at 8:17 PM | globenewswire.com

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky

August 28 at 4:42 PM | globenewswire.com

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 28 at 4:00 PM | globenewswire.com

Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL

August 28 at 11:27 AM | theglobeandmail.com

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPL

August 28 at 8:45 AM | prnewswire.com

Price T Rowe Associates Inc. MD Sells 109,051 Shares of Replimune Group, Inc. $REPL

August 28 at 5:06 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

August 27 at 5:58 PM | prnewswire.com

September 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPL

August 27 at 4:29 PM | globenewswire.com

Kirby McInerney LLP Reminds Replimune Group, Inc. Investors of Class Action Filing and Encourages Investors to Contact the Firm

August 27 at 4:19 PM | globenewswire.com

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman

August 27 at 1:20 PM | globenewswire.com

Nuveen LLC Acquires Shares of 671,411 Replimune Group, Inc. $REPL

August 27 at 3:38 AM | marketbeat.com

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL

August 26, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

August 25, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EQ, ITOS, CYRX, and REPL Company Descriptions

CryoPort NASDAQ:CYRX

$8.86 +0.17 (+1.96%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.86 0.00 (0.00%)

As of 08/29/2025 07:50 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Equillium NASDAQ:EQ

$1.74 -0.08 (-4.40%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.69 -0.05 (-3.10%)

As of 08/29/2025 07:55 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

iTeos Therapeutics NASDAQ:ITOS

$10.15 0.00 (0.00%)

As of 08/29/2025

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Replimune Group NASDAQ:REPL

$5.40 +0.02 (+0.37%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.40 -0.01 (-0.09%)

As of 08/29/2025 07:54 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time